Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of Clinical Pharmacology
Xiaoli WangCharles Frost

Abstract

An open-label, parallel-group, single-dose study was conducted to assess the pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end-stage renal disease (ESRD) on hemodialysis compared with 8 subjects with normal renal function. A single oral 5-mg dose of apixaban was administered once to healthy subjects and twice to subjects with ESRD, separated by ≥7 days: 2 hours before (on hemodialysis) and immediately after a 4-hour hemodialysis session (off hemodialysis). Blood samples were collected for determination of apixaban pharmacokinetic parameters, measures of clotting (prothrombin time, international normalized ratio, activated partial thromboplastin time), and anti-factor Xa (FXa) activity. Compared with healthy subjects, apixaban Cmax and AUCinf were 10% lower and 36% higher, respectively, in subjects with ESRD off hemodialysis. Hemodialysis in subjects with ESRD was associated with reductions in apixaban Cmax and AUCinf of 13% and 14%, respectively. The percent change from baseline in clotting measures was similar in healthy subjects and subjects with ESRD, and differences in anti-FXa activity were similar to differences in apixaban concentration. A single 5-mg oral dose of apixaban was well tolerat...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Dec 24, 2010·The New England Journal of Medicine·Michael Rud LassenUNKNOWN ADVANCE-3 Investigators
Feb 12, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN AVERROES Steering Committee and Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Dec 12, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY-EXT Investigators
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Jul 25, 2013·Clinical Advances in Hematology & Oncology : H&O·Jeffrey Weitz
Apr 5, 2014·British Journal of Clinical Pharmacology·Charles FrostFrank LaCreta
Jun 26, 2014·Expert Opinion on Drug Metabolism & Toxicology·Thomas J Velenosi, Bradley L Urquhart
Sep 12, 2015·Journal of Clinical Pharmacology·Ming ChangCharles E Frost

❮ Previous
Next ❯

Citations

Mar 21, 2016·American Heart Journal·An S De VriesePaolo Raggi
Mar 31, 2016·Current Neurology and Neuroscience Reports·Sofya KuznetsovSri K Madan Mohan
Jan 13, 2015·Clinical Pharmacokinetics·Charles E FrostFrank LaCreta
Jun 18, 2016·Journal of the American College of Cardiology·Kevin E ChanJonathan P Piccini
Nov 1, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Nisha Bansal
Dec 22, 2016·The New England Journal of Medicine·Stuart J ConnollyMark Crowther
Nov 20, 2016·Clinical Transplantation·David M SalernoJaclyn McKeen
Jun 28, 2016·Therapeutic Advances in Cardiovascular Disease·Benjamin E PetersonChristopher B Granger
Apr 10, 2017·The American Journal of Medicine·Caitlin M Gibson, Shannon W Finks
Jan 25, 2017·The Annals of Pharmacotherapy·William E Dager, Jin A Lee
May 16, 2017·The American Journal of Medicine·John FanikosPaul P Dobesh
Jun 28, 2017·Therapeutic Advances in Cardiovascular Disease·Alexander G G TurpieAntonio Ciaccia
Feb 27, 2016·The Annals of Pharmacotherapy·Shannon W FinksPaul P Dobesh
Mar 27, 2018·Nature Reviews. Nephrology·Tatjana S PotparaGregory Y H Lip
Feb 20, 2018·British Journal of Clinical Pharmacology·Satoshi UeshimaToshiya Katsura
Mar 27, 2018·Pacing and Clinical Electrophysiology : PACE·Ronpichai ChokesuwattanaskulWisit Cheungpasitporn
Nov 3, 2017·Canadian Journal of Kidney Health and Disease·Chieh TsaiMarisa Battistella
Dec 19, 2017·Journal of Atrial Fibrillation·Justin Hayase, Noel G Boyle
Dec 19, 2017·Journal of Atrial Fibrillation·Anna Plitt, Sameer Bansilal
Jun 7, 2018·The Annals of Pharmacotherapy·Joseph H SchaferBritta A Staubes
Jun 13, 2018·American Journal of Nephrology·Lili ChanGirish N Nadkarni
May 31, 2018·Journal of Thrombosis and Thrombolysis·Michael BowieMinh-Ha Tran
Jul 26, 2018·British Journal of Haematology·Kenneth T Moore
Aug 8, 2018·Therapeutic Advances in Cardiovascular Disease·Zachary A Stacy, Sara K Richter
Sep 6, 2018·British Journal of Haematology·Kathrine Parker, Jecko Thachil
Jan 28, 2018·Journal of the American Heart Association·Konstantinos N Aronis, Elaine M Hylek
Nov 1, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Peter A McCulloughManish D Assar
May 29, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Nishank Jain, Robert F Reilly
Mar 18, 2017·Journal of the American Society of Nephrology : JASN·Thomas A MavrakanasMark L Lipman
Jul 14, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Jung-Im ShinMorgan E Grams
Dec 30, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Katherine G GarloKevin E Chan
Jun 7, 2017·Journal of the American Society of Nephrology : JASN·Eli N Deal, Jerrica E Shuster
Mar 18, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Alexandru BurlacuAdrian Covic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.